High Content Analysis & Phenotypic Screening
February 11 - 12, 2016 - San Diego MA USCambridge Healthtech Institute
hohrenberger@healthtech.com
Phone:7819725400
Fax:7819725400
Cambridge Healthtech Institute’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program and two dedicated tracks. The High-Content Analysis track will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Phenotypic Screening track will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Featured Speakers Include: - Paul Andrews, Director, National Phenotypic Screening Centre, University of Dundee - Anthony M. Davies, Director, Translational Cell Imaging, Queensland University of Technology - Erik Hett, Team Leader, Chemical & Molecular Therapeutics, Biogen - Susanne Heynen-Genel, Director, High-Content Screening, Sanford Burnham Prebys Medical Discovery Institute - Zhuyin Li, Team Lead, Lead Discovery & Optimization, Bristol-Myers Squibb - Ulrich Schopfer, Head, Integrated Lead Discovery, Novartis - D. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute - Alan Waggoner, Director, Molecular Biosensor and Imaging Center, Carnegie Mellon University - Wei Zheng, Group Leader, Preclinical Innovation, NCATS Join the original High-Content Analysis event and get access to two concurrent conference tracks featuring cutting-edge scientific agendas, an expanded exhibit hall, technology showcases and interactive dinner courses.